2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug-Drug Interactions, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Diseases, Bleeding and Clotting, Bleeding Disorders, Hemophilia, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Genetic Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Infectious Diseases, Metabolic Disorders, Iron Deficiency, Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Pregnant, Young Adult
PAPER

2707 Not so benign? sleep and social functioning in immune thrombocytopenia and immune thrombotic thrombocytopenic purpura

Honieh Sowdagar, MPH, Sara Vesely, PhD, MPH2, Deirdra Terrell Jr, PhD3, Mohamad Khawandanah, MD4
1 University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
2 University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
3 University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
4 OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

Introduction Although sleep is essential for optimal health, chronic illness or surviving a life-threatening disorder contributes to sleep problems. Patients with immune thrombocytopenia (ITP) and immune-mediated thrombotic thrombocytopenic purpura (iTTP) often describe challenges with fatigue. In our previous qualitative study, iTTP survivors also reported an inability to return to previous levels of activity/social roles. Impaired social connection is associated with premature mortality. Our goal was to assess sleep and social function in ITP and iTTP patients.

 

Methods A cross-sectional study of patients from the Oklahoma ITP and iTTP Registries. Sleep disturbance and social function were assessed with validated Patient-Reported Outcomes Measurement Information System (PROMIS) measures. The survey included: demographics, medical history, PROMIS sleep disturbance (8-item), and PROMIS ability to participate in social roles/activities (8-item). The sleep survey asked satisfaction, ability and quality of sleep (past 7 days) with a Likert scale from ‘Not at All’ to ‘Very much’. Social function focused on roles/activities and satisfaction with engagement (family/friends, work/leisure). Likert scale from ‘Never’ to ‘Always’ (no timeframe).

PROMIS has a US mean 50 (SD 10), with higher scores on the sleep survey indicating worse function but lower scores on the social function indicating worse function. Sleep impairment was defined as a composite outcome (documented sleep issue [sleep apnea, narcolepsy, sleep medication] or mean score ≥55 on the sleep survey). Impaired social function was defined as mean score < 45 (half SD below US mean) on the social function survey. Active ITP was defined as platelet < 100K/µL or current treatment. iTTP patients were considered in remission.

Subgroup/disease descriptive comparisons were made.

 

Results 54 patients (35 ITP; 19 iTTP) completed the study. ITP mean age 59 years, iTTP mean age 58 years. Most patients were White (89% ITP; 58% iTTP) and female (74% ITP; 68% iTTP). Eleven ITP patients were on treatment (steroids, thrombopoietic agents, mycophenolate mofetil, rilzabrutinib, IVIG, danazol), with 1 iTTP patient on rituximab.  

 

Overall sleep disturbance means were similar to the US mean of 50 and each other- ITP mean 53 (95% confidence interval (CI) 49, 56), iTTP mean 52, (95% CI 47, 57). However, when impaired sleep was defined as a composite outcome (mean >55 or sleep medication or previous diagnosis) 49% (95% CI 31, 66; n=17) ITP patients and 47% (95% CI 24, 71; n=9) iTTP patients had impaired sleep. In comparison, impaired sleep reported in US adults in 2024 was 15% difficulty falling asleep, 18% trouble staying asleep.

 

Subgroup comparisons in ITP patients with sleep impairment to those without: 88% female with impairment vs 61% without; 41% active disease with impairment vs 44% without; 29% > 65 years with impairment vs 28% without.

 

Subgroup comparisons in iTTP with sleep impairment to those without: 67% female with impairment vs 70% female without; 33% Black race with impairment vs 40% without; 33% > 65 years with impairment vs 50% without.

 

Overall mean scores for social function- ITP mean 52 (95% CI 48, 55), iTTP mean 49 (95% CI 45, 54). However, 31% (95% CI 17, 49; n=11) of ITP patients had impaired social function. Among iTTP, 42% (95% CI 20, 67; n= 8) had impaired social function.

 

Subgroup comparisons in ITP patients with impaired social function to those without: 82% female with impaired function vs 71% without; 36% active disease with impaired function vs 46% without; 45% > 65 years with impaired function vs 21% without.

 

Subgroup comparisons in iTTP patients with impaired social function to those without: 75% female with impairment vs 64% without; 38% Black race with impairment vs 36% without; 25% > 65 years with impairment vs 55% without.

 

Conclusion ITP and iTTP patients suffer from more sleep impairment than expected when compared to US estimates. In ITP patients, sleep impairment was descriptively more prevalent in females, while descriptively more prevalent in younger iTTP patients. ITP patients with worse social function were descriptively more female and older compared to those without impairment.  While iTTP patients with impaired social function were descriptively more female and less likely > 65 years of age. Although our study was limited by a small sample size, these results support qualitative patient perceptions and should be assessed during routine follow-up. 

Deirdra Terrell Jr, PhD: No relevant conflicts of interest to declare.